|
Cardiology / Original Article
Effect of tegoprazan on temporal variability of platelet reactivity in patients treated with clopidogrel after coronary stenting
Oh-Hyun Lee, Ji Woong Roh, Yongcheol Kim, Eui Im, Deok-Kyu Cho
Korean J Intern Med. 2025;40(5):759-766. Published online March 25, 2025
Background/Aims: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity.
Methods: Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were ..
|
|
|
Cardiology / Original Article
Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
Hyung Joon Joo, Ji-Young Park, Soon Jun Hong, Kyoung-Ah Kim, Seung Hoon Lee, Jae-Young Cho, Jae Hyoung Park, Cheol Woong Yu, Do-Sun Lim
Korean J Intern Med. 2018;33(3):522-531. Published online October 19, 2017
Background/Aims: Although epigallocatechin-3-gallate (EGCG), which is found in high contents in the dried leaves of green tea, has been reported to have an anti-platelet effect, synergistic effects of EGCG in addition to current anti-platelet medications remains to be elucidated.
Methods: Blood sam..
|
|
|
Cardiology / Original Article
Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation
Yun-Kyeong Cho, Chang-Wook Nam, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Seung-Ho Hur, Yoon-Nyun Kim, Jang-Hoon Lee, Dong-Heon Yang, Bong-Ryeol Lee, Byung-Chun Jung, Woong Kim, Jong-Seon Park, Jin-Bae Lee, Kee-Sik Kim, Kwon-Bae Kim
Korean J Intern Med. 2014;29(2):210-216. Published online February 27, 2014
Background/Aims: Combination single-pill therapy can improve cost-effectiveness in a typical medical therapy. However, there is a little evidence about the efficacy and tolerability of combination single-pill antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stent..
|
|
|
Original Article
Detection of Clopidogrel Hyporesponsiveness Using a Point-of-Care Assay and the Impact of Additional Cilostazol Administration after Coronary Stent Implantation in Diabetic Patients
Tae-Hyun Yang, Doo-Il Kim, Dong-Kie Kim, Jae-Sik Jang, Ung Kim, Sang-Hoon Seol, Dae-Kyeong Kim, Geu-Ru Hong, Jong-Seon Park, Dong-Gu Shin, Young-Jo Kim, Yun-Kyeong Cho, Chang-Wook Nam, Seung-Ho Hur, Kwon-Bae Kim, Dong-Soo Kim
Korean J Intern Med. 2011;26(2):145-152. Published online June 1, 2011
Background/AimsImpaired responsiveness to clopidogrel is common in patients with type 2 diabetes mellitus (DM). The aim of this study was to evaluate the clinical application of a point-of-care assay to detect impaired responsiveness to clopidogrel after coronary stent implant..
|
|
|
Original Article
The Impact of Generic Clopidogrel Bisulfate on Platelet Inhibition in Patients with Coronary Artery Stents: Results of the ACCEL-GENERIC Study
Young-Hoon Jeong, Jin-Sin Koh, Min-Kyung Kang, Yeon-Jeong Ahn, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang
Korean J Intern Med. 2010;25(2):154-161. Published online June 1, 2010
Background/AimsIn patients with coronary artery stents, the cost of clopidogrel has been cited as a factor in the premature discontinuation of therapy. Thus, the introduction of lower-cost generic clopidogrel may increase patient compliance. However, platelet inhibition by ge..
|
|
|
Original Article
Comparison of antiplatelet treatment in patients with clopidogrel nonresponders with or without carriage of CYP2C19 polymorphism
[retracted-article]
Yun Myoung Ko, Jeong Kyung Kim, Jeong Hee Kim, Sang-Ho Park, Rak Kyeong Choi
Received October 31, 2017 Accepted January 8, 2018 Published online May 31, 2018
Background/Aims: Several interventions exist for overcoming high platelet reactivity (HPR) on clopidogrel therapy. The goal of this study was to identify strategies that improve inhibition of platelet reactivity in clopidogrel nonresponders with or without loss of function CYP2C19 genotypes, ..
|
|
|
